Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Montréal, QC H3T 1E2, Canada.
Division of Experimental Medicine, McGill University, Montréal, QC H4A 3J1, Canada.
Sci Adv. 2023 Aug 9;9(32):eadf4082. doi: 10.1126/sciadv.adf4082.
Interstrand DNA cross-links (ICLs) represent complex lesions that compromise genomic stability. Several pathways have been involved in ICL repair, but the extent of factors involved in the resolution of ICL-induced DNA double-strand breaks (DSBs) remains poorly defined. Using CRISPR-based genomics, we identified FIGNL1 interacting regulator of recombination and mitosis (FIRRM) as a sensitizer of the ICL-inducing agent mafosfamide. Mechanistically, we showed that FIRRM, like its interactor Fidgetin like 1 (FIGNL1), contributes to the resolution of RAD51 foci at ICL-induced DSBs. While the stability of FIGNL1 and FIRRM is interdependent, expression of a mutant of FIRRM (∆WCF), which stabilizes the protein in the absence of FIGNL1, allows the resolution of RAD51 foci and cell survival, suggesting that FIRRM has FIGNL1-independent function during DNA repair. In line with this model, FIRRM binds preferentially single-stranded DNA in vitro, raising the possibility that it directly contributes to RAD51 disassembly by interacting with DNA. Together, our findings establish FIRRM as a promoting factor of ICL repair.
链间 DNA 交联 (ICLs) 代表了危及基因组稳定性的复杂损伤。已有多种途径参与 ICL 修复,但参与解决 ICL 诱导的 DNA 双链断裂 (DSBs) 的因素的程度仍未明确定义。我们使用基于 CRISPR 的基因组学方法,鉴定出 FIGNL1 相互作用的重组和有丝分裂调节剂 (FIRRM) 是 ICL 诱导剂 mafosfamide 的敏化剂。从机制上讲,我们表明 FIRRM 与其相互作用蛋白 Fidgetin like 1 (FIGNL1) 一样,有助于解决 ICL 诱导的 DSB 处的 RAD51 焦点。虽然 FIGNL1 和 FIRRM 的稳定性相互依赖,但表达一种突变型 FIRRM (∆WCF),其在没有 FIGNL1 的情况下稳定蛋白,可使 RAD51 焦点和细胞存活得到解决,这表明 FIRRM 在 DNA 修复过程中具有 FIGNL1 独立的功能。与该模型一致,FIRRM 在体外优先结合单链 DNA,这增加了其通过与 DNA 相互作用直接有助于 RAD51 解组装的可能性。总之,我们的研究结果确立了 FIRRM 作为 ICL 修复的促进因子。